AbCellera Biologics Inc.
ABCL
Rank in Stocks
#4144
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Share Price
$11.99
Last synced: 2026-10-19
Market Cap
$3.88B
Change (1 day)
1.57%
Change (1 year)
104.52%
Country
CA
Trade AbCellera Biologics Inc. (ABCL)
Category
Healthcare
Revenue for AbCellera Biologics Inc. (ABCL)
Revenue in Jun 2026 TTM: $66.17M
According to AbCellera Biologics Inc. latest financial reports the company's current revenue (TTM) is $66.17M. In 2023 the company made a revenue of $38.03M a decrease compared to the revenue in the year 2022 that was $485.42M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbCellera Biologics Inc. from 2018 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $66.17M | 129.50% |
| 2024 | $28.83M | -24.17% |
| 2023 | $38.03M | -92.17% |
| 2022 | $485.42M | 29.38% |
| 2021 | $375.20M | 60.92% |
| 2020 | $233.16M | 1,907.88% |
| 2019 | $11.61M | 31.49% |
| 2018 | $8.83M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 18,977.72% |
US
|
|
| $2.23B | 3,266.93% |
US
|
|
| $15.74B | 23,692.68% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 8,999.31% |
NL
|
